期刊文献+

临床诊断与集团筛查前列腺癌的病理学特征比较

Comparison of pathological features of prostate cancer between mass screening patients and clinical patients
下载PDF
导出
摘要 目的:通过对临床诊断与集团筛查前列腺癌的病理学特征的比较,探讨人群筛查前列腺癌的必要性。方法:107例前列腺癌组织,其中51例为临床病理标本,56例为经前列腺特异抗原(PSA)筛查后发现的病理标本。其中7例前列腺上皮内瘤(PIN)均来自集团筛查的标本。应用Gleason分级与评分标准进行病理学分析。结果:①筛查组前列腺癌的Gleason分级明显低于临床组(χ2=48.22,P<0.001)。②筛查组前列腺癌的Gleason评分明显低于临床组(χ2=24.55,P<0.001)。③筛查组前列腺癌的分化程度明显高于临床组(χ2=22.46,P<0.001)。④最典型的PIN仅见于集团筛查因PSA含量进行性增高接受活检穿刺患者标本中。结论:人群筛查病例中病理组织学变化以中期的中分化癌为多见,而临床病例中则以晚期的低分化癌为主,PSA集团检查有益于前列腺癌的早期发现。 Objeotive To investigate the role of the mass screening by comparing the pathological features of prostate cancer between mass screening patients and clinical patients. Methods 107 cases of prostate cancer (including 51 patients from clinical diagnosis and 56 patients from mass screening) and 7 cases of prostate intraepithelial neoplasia (PIN, from mass screening) were analyzed using the Gleason's grade system. Results (1) Gleason' s grade of prostate cancer in mass screening group was lower than that in clinical diagnosis group (χ^2 =48.22, P〈0. 001); (2) Gleason' s scores of prostate cancer in mass screening group were lower than those in clinical diagnosis group (χ^2=24. 55, P〈0. 001); (3) Differentiated degrees of prostate cancer in mass screening group were higher than those in clinical diagnosis group (χ^2=22.46, P〈0. 001) ; (4) The typical PIN was found only in mass screening group. Conolusion In mass screening group the moderately differentiated carcinoma is the most common type of prostate cancer, but in clinical diagnosis group the poorly differentiated carcinoma is most. General investigation for prostate cancer is benefit to find caner of early stage.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2008年第5期879-882,924,共5页 Journal of Jilin University:Medicine Edition
基金 日本JICA项目资助课题(科技部第59号) 中国科技部国际科技合作重点资助课题(2004DFB0200)
关键词 前列腺肿瘤 GLEASON分级 前列腺特异性抗原 prostatic neoplasms Gleason's grade prostate-specific antigen
  • 相关文献

参考文献10

  • 1Sooriakumaran P, Lovell DP, Henderson A, et al. Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer [J]. Clin Oncol (R Coll Radiol), 2005, 17 (8): 655-658.
  • 2Shirley SE Escoffery CT Sargeant LA , et aI. Clinicopathological features of prostate cancer in Jamaican men [J].BJU Int , 2002 , 89 (4) : 390-395.
  • 3Salirrosas SV, Armborgo J, Mostacero M. Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer[J].Acta Chir Iugosl, 2005,52 (4): 13-17.
  • 4Shizuka O , Satoh T , Kobayashi S , et al. Mass screening for prostate cancer in Nagano[J].Hinyokika Kiyo, 2001, 47 (11) :769-772.
  • 5王洪亮,张海峰,许宁,张灵,计国义,李晓萌,高洪文,赵雪俭,桑原正明.中日两城市前列腺癌普查结果及临床病理对比研究[J].中国老年学杂志,2005,25(2):144-146. 被引量:8
  • 6张灵,计国义,李晓萌,李胜文,高洪文,甘卉,王洪亮,潘玉琢,孔祥波,桑原正明,赵雪俭.前列腺癌集团检诊对临床前列腺癌诊断的影响[J].中华泌尿外科杂志,2004,25(2):103-105. 被引量:41
  • 7Kuwahara M, Tochigi T, Kawamura S, et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China[J]. Urology, 2003 , 61 (1): 137 -141.
  • 8Brassell SA, Kao TC, Sun L, et al. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer[J]. Urology, 2005, 66 (6): 1229-1233.
  • 9杨俊福,程传宇,武玉东,赵亚兵,梁宏,魏金星.前列腺癌患者癌组织前列腺干细胞抗原、血清前列腺特异抗原检测[J].郑州大学学报(医学版),2007,42(4):717-719. 被引量:3
  • 10Constantinou J, Feneley MR. PSA testing: an evolving relationship with prostate cancer screening[J]. Prostate Cancer Prostatic Dis, 2006, 9 (1): 6-13.

二级参考文献14

  • 1邓杰,高玉堂,谢桐,王跃闵,程家蓉,方茹蓉,赵葆华,Ann Hsing,沈铭昌.前列腺癌的临床流行病学研究[J].肿瘤,1995,15(4):340-342. 被引量:4
  • 2[1]Kumar-Sinha C,Chinnaiyan AM.Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer[J].Urology,2003,62(Suppl 1):19
  • 3[2]Tavtigian SV,Simard J,Teng DH,et al.A candidate prostate cancer susceptibility gene at chromosome 17p[J].Nat Genet,2001,27(2):172
  • 4[3]Zhigang Z,Wenlv S.Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues:implications for prostate carcinogenesis and progression of prostate cancer[J].Jpn J Clin Oncol,2004,34(7):414
  • 5[4]Valdman A,Fang X,Pang ST,et al.Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer[J].Prostate,2004,60(4):367
  • 6[5]Luo J,Zha S,Gage WR,et al.Alpha-methylacyl-CoA racemase:a new molecular marker for prostate cancer[J].Cancer Res,2002,62(8):2 220
  • 7[6]Reiter RE,Gu ZN,Watabe T,et al.Prostate stem cell antigen:a cell surface marker overexpressed in prostate cance[J].Proc Natl Acad Sci USA,1998,95(4):1 735
  • 8[7]Saffran DC,Raitano AB,Hubert RS,et al.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts[J].Proc Natl Acad Sci USA,2001,98(5):2 658
  • 9[8]Stamey TA.Preoperative serum prostate-specific antigen (PSA) below 10microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure[J].Clin Chem,2001,47(4):631
  • 10黄甫初,钟惟德,刘建平,沈昌理.前列腺癌130例治疗分析[J].中华泌尿外科杂志,1997,18(4):231-233. 被引量:23

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部